Skip to main content
OpenTrials
Completed

NCT Number: NCT05460013

Impact of Oral Nutritional Supplements on Patients Undergoing Haematopoietic Stem Cell Transplantation

Malnutrition is common after haematopoietic stem cell transplantation (HSCT), and is a well-known prognostic factor for survival. HSCT-associated treatments are metabolic and digestively intolerant, hence can induce a significant reduction in oral intake. Thus weight loss, as well as a reduction in serum albumin, and pre-albumin levels, are frequent following HSCT. Although the gut remains functional, sore mouth, mucositis, dysphagia, nausea, vomiting, and diarrhoea will inevitably hinder the implementation of enteral nutrition (EN), thus leading to a deficit between daily intake and requirement. Side effects of chemotherapy and antibiotics in combine will contribute to the alteration of intestinal flora on top of the existing gut symptoms, further impairing nutrient digestion and absorption.

Oral nutritional supplements (ONS) are foods for special medical purposes (FSMP) that are specially formulated for oral nutritional support. Limited retrospective studies performed in Western countries have found that ONS was tolerable for HSCT patients eligible for EN, however, the data is sparse in China to support the safety of usage amongst this population. On the other side, what is less clear is the nature of soluble fiber upon the intestinal microenvironment in patients undergoing HSCT. It would be worthwhile to investigate the impact of fibre-modulated ONS on gut function and symptoms.

The study is a prospective study. All the participants will be recruited from a single research center (Renji Hospital). The participants will be randomized into two groups: traditional treatment or ONS. Ensure complete (Abbott), which contains soluble dietary fiber such as fructo-oligosaccharide (FOS) and inulin, will be served as the ONS for testing.

The primary aim of the study is to examine the between-group change from baseline body weight at 28 days post-transplantation. The secondary outcomes include the within-group and between-group dynamic change in the peri-transplant period for the following: body weight, fat-free mass, circumference, handgrip test, and patient-generated global subjective assessment. The tolerability of supplementing ONS and its' effect on gut function as well as on infection rate is also of interest.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–75 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine

Shanghai, Shanghai Municipality, 200124, China

About this study

Standard Operating Procedures:

The study is located in Renji Hospital Stem Cell Transplant Unit, including Haematology Outpatient Department and Clinical Nutrition Department. All the patients aged between 18 and 75 years planned for HSCT and who are able to understand and sign an informed consent form are eligible for the study. The potential participants will be provided with the information sheet by the dietitian on the day of their outpatient pre-assessment visit. Each participant will be allocated with a study-specific code to protect their confidentiality. After recruitment, the participants will be asked to consume either the placebo control OR the ONS for testing, intended for supplementation for the duration of 7 days prior to HSCT admission. Anthropometry, biochemistry, and functional assessments are planned at four time points: before admission (baseline), the day of transplantation (D0), 14 days post-transplantation (D14) and 28 days post-transplantation (D28). In addition, nutritional intakes and gut assessments will be collected for the duration of the whole admission. If a subject is discharged home before D14 or D28, then these will be attempted at the appropriate time when the patient attended Haematology Outpatients for medical follow-up visits. Teleconsultation might be involved if the visit is not possible. All the data will be stored in an electronic database. It will be password protected with access only restricted to major investigators. All adverse events occurring within the trial will be collected at each visit for assessment of safety.

Sample Size Assessment:

A total number of 100 participants is determined necessary to demonstrate an effect. This sample size is designed to provide 85% power to detect a 1.2kg difference in body weight using an alpha=0.05(two-sided) to account for comparisons.

Plan for missing data:

A variable could be reported as missing by reasons possibly associated with logistic issues or participants declined to take the measurements. Strategy to minimize missing data includes setting up planning and time schedule in the Excel sheet to keep all the investigators notified.

Statistical Analysis Plan:

The demographic and clinical characteristics of patients will be summarized using descriptive statistics. Data analysis will be carried out using Statistical Analysis System (SAS) 9.4. Statistical analysis software. The mean or median change in continuous variables between the group by time points is assessed using t-test or Wilcoxon's rank sum test. Changes in categorical variables is assessed using Pearson chi-square or McNemar's test. Analysis of covariance or Analysis of variance might be applied as needed.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Planned for HSCT
  • No contraindications to enteral nutrition
  • Able to consent

Exclusion criteria

  • Existing contraindications to enteral nutrition
  • Existing infectious diarrhoea
  • Had other malignancies
  • Had gut surgery in a year
  • Had used prebiotics or probiotics or synbiotic in a month
  • Immunosuppressive OR prolonged corticosteroid therapy (more than three months)
  • Pregnancy or lactation
  • Had an allergy, or intolerance to ingredients of dietary supplements
  • Judged to be unsafe to tolerate fiber

Treatment and study plan

Traditional Control

Dietary Supplement

Placebo control is a compounded made-up shake that is traditionally used by the Haematology ward to supplement patients receiving HSCT. The control provides an equivalent of 500kcals and 20.6g protein, 3.4g fiber per day. The participants will be randomly assigned to consume the control twice daily for the duration of 7 days prior to the admission to the day of discharge.

Oral Nutritional Supplement

Dietary Supplement

The product to be studied is a standard polymeric formula. It is intended to provide 500cals, 18.4g protein, and 5g fiber per day. The fiber contained is mostly presented in the form of soluble fiber (inulin, fructo-oligosaccharide). The participants will be randomly assigned to consume the intervention twice a day for the duration of 7 days prior to the admission to the day of discharge.

Other names: Ensure Complete (Abbott)

Primary outcomes

  1. The Between-group Change for Body Weight

    Time frame: It compares the change in body weight between two timepoints ( at baseline and at 28 days post transplantation) between two arms

    It quantifies the difference in weight change between the groups. Body weight is assessed in kilograms.

Secondary outcomes

  1. The Within-group Change for Body Weight (Ensure)

    Time frame: It measures the change in body weight within the Ensure group from baseline to three time points post-transplantation, namely the day of transplantation, 14 days post transplantation and 28 days post transplantation

    It measures the within-group change for body weight in the ensure group. Body weight is assessed in kilograms

  2. The Within-group Change for Body Weight (Control)

    Time frame: It measures the change in body weight within the control group from baseline to three time points post-transplantation, namely the day of transplantation, 14 days post transplantation and 28 days post transplantation

    It measures the within-group change for body weight in the control group. Body weight is assessed in kilograms

  3. The Between-group and Within-group Change for Fat-free Mass

    Time frame: The fat-free mass was measured at baseline and at 28 days post transplantation. Then the change from baseline to 28 days post transplantation were compared.

    It measures the between-group and within-group change for Fat-free mass. Fat-free mass is assessed in kilograms.

  4. The Between-group and Within-group Change for Calf Circumference

    Time frame: The calf circumference was measured at baseline, at the day of transplantation, 14 days post transplantation and 28 days post transplantation. Then the change from baseline to these three timepoints were compared.

    It measures the between-group and within-group change for calf circumference. Calf circumference is assessed in centimeters.

  5. It Measures the Between-group and Within-group Change for the Handgrip Test.

    Time frame: The handgrip test was conducted at baseline, at the day of transplantation, 14 days post transplantation and 28 days post transplantation. Then the change from baseline to these three timepoints were compared.

    It measures the between-group and within-group change for the handgrip test. Handgrip test is assessed in kilograms.

  6. The Within-group and Between-group Change for Patient-Generated Subjective Global Assessment

    Time frame: PG-SGA was conducted at baseline and at 28 days post transplantation. Then the change in PG-SGA scores between these two timepoints were compared.

    Patient-Generated Subjective Global Assessment (PG-SGA) is a universally used nutritional assessment tool. An additive score is used to define specific nutritional interventions. Scale title is nutritional triage recommendations, with the score of 0 referring to no intervention required at this time and more than 9 scores indicating a critical need for intervention. Of note, the minimum value is 0 and there is no maximum value. A higher value means a worse outcome.

  7. The Within-group and Between-group Change for Microbiota Diversity

    Time frame: The stool samples were collected at the time of laminar room admission and 14 days post transplantation. Then the change in alpha-diversity index between this two time-points were compared.

    The alpha diversity index is a quantitative measure that reflects the number of different bacterial species present in a sample. The index is unitless, it is a pure number derived from proportions. The index can be interpreted through sobs, shannon, and simpson index. Sobs index is the raw count of species (distinct microbial types), with higher number indicating a higher richness. Shannon index is calculated from the proportion of each species, with no range exists. The simpson index is a probability (range 0-1), with higher values indicating less abundant species.

  8. The Within-group Change for Microbiota-derived Metabolites in Urine

    Time frame: The microbiota-derived metabolites were collected at the time of laminar room admission and 14 days post transplantation. Then the change in concentration between this two time-points were compared.

    The diversity is assessed through urine samples. For practical considerations, urine samples were collected at the time of laminar room admission and discharge, respectively.

  9. The Between-group Change for the Infection Rate

    Time frame: For the duration between the day of transplantation to 14 days of transplantation (approximate engraftment time)

    The infection rate is assessed as the number of diagnosed infections. The infection rate is determined through a comprehensive analysis of respiratory, blood, stool, and urine tests, with a positive result in any one of these tests leading to a diagnosis of an infection.

  10. The Within-group and Between-group Change for Gut Symptoms

    Time frame: The information on stool frequency and consistency was collected daily for the duration between the day of transplantation to 14 days post transplantation.

    Gut symptoms is assessed through the presence of diarrhoea in percentage. Diarrhoea was defined as the passage of more than 3 times loose stools daily.

  11. The Tolerability of Supplementing the Standard Polymeric Formula in the Targeted Population

    Time frame: For the duration between the baseline to 28 days post transplantation

    The tolerability of supplementing the standard polymeric formula in the targeted population. This refers to the dropout rate related to intolerance.

Sponsors and collaborators

Lead sponsor

RenJi Hospital

Other

Registry information

Official study title

Impact of Oral Nutritional Supplements on Nutritional, Gut Functional and Clinical Outcomes: a Randomized Controlled Trial in Patients Undergoing Haematopoietic Stem Cell Transplantation

Important dates

Study start
2022
Primary completion
2025
Study completion
2026
First posted
Jul 15, 2022
Registry last updated
May 11, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.